Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Statins Do Not Directly Inhibit the Activity of Major Epigenetic Modifying Enzymes.

Bridgeman S, Northrop W, Ellison G, Sabapathy T, Melton PE, Newsholme P, Mamotte CDS.

Cancers (Basel). 2019 Apr 10;11(4). pii: E516. doi: 10.3390/cancers11040516.

2.

Use of virus-like particles as a native membrane model to study the interaction of insulin with the insulin receptor.

Sabapathy T, Helmerhorst E, Bottomley S, Babaeff S, Munyard K, Newsholme P, Mamotte CD.

Biochim Biophys Acta Biomembr. 2019 Jun 1;1861(6):1204-1212. doi: 10.1016/j.bbamem.2019.03.021. Epub 2019 Apr 2.

PMID:
30951702
3.

The Regulatory Status Adopted by Lymph Node Dendritic Cells and T Cells During Healthy Aging Is Maintained During Cancer and May Contribute to Reduced Responses to Immunotherapy.

Gardner JK, Jackaman C, Mamotte CDS, Nelson DJ.

Front Med (Lausanne). 2018 Nov 30;5:337. doi: 10.3389/fmed.2018.00337. eCollection 2018.

4.

Elderly dendritic cells respond to LPS/IFN-γ and CD40L stimulation despite incomplete maturation.

Gardner JK, Cornwall SMJ, Musk AW, Alvarez J, Mamotte CDS, Jackaman C, Nowak AK, Nelson DJ.

PLoS One. 2018 Apr 13;13(4):e0195313. doi: 10.1371/journal.pone.0195313. eCollection 2018.

5.

Epigenetic effects of metformin: From molecular mechanisms to clinical implications.

Bridgeman SC, Ellison GC, Melton PE, Newsholme P, Mamotte CDS.

Diabetes Obes Metab. 2018 Jul;20(7):1553-1562. doi: 10.1111/dom.13262. Epub 2018 Mar 22. Review.

PMID:
29457866
6.

Modulation of dendritic cell and T cell cross-talk during aging: The potential role of checkpoint inhibitory molecules.

Gardner JK, Mamotte CDS, Jackaman C, Nelson DJ.

Ageing Res Rev. 2017 Sep;38:40-51. doi: 10.1016/j.arr.2017.07.002. Epub 2017 Jul 20. Review.

PMID:
28736117
7.

Pleiotropic and Adverse Effects of Statins-Do Epigenetics Play a Role?

Allen SC, Mamotte CDS.

J Pharmacol Exp Ther. 2017 Aug;362(2):319-326. doi: 10.1124/jpet.117.242081. Epub 2017 Jun 2. Review.

PMID:
28576976
8.

Mesothelioma tumor cells modulate dendritic cell lipid content, phenotype and function.

Gardner JK, Mamotte CD, Patel P, Yeoh TL, Jackaman C, Nelson DJ.

PLoS One. 2015 Apr 17;10(4):e0123563. doi: 10.1371/journal.pone.0123563. eCollection 2015.

9.

Plasma cholesterol in adults with phenylketonuria.

Williams RA, Hooper AJ, Bell DA, Mamotte CD, Burnett JR.

Pathology. 2015 Feb;47(2):134-7. doi: 10.1097/PAT.0000000000000210.

PMID:
25551302
10.

Lipid-laden partially-activated plasmacytoid and CD4(-)CD8α(+) dendritic cells accumulate in tissues in elderly mice.

Gardner JK, Mamotte CD, McGonigle T, Dye DE, Jackaman C, Nelson DJ.

Immun Ageing. 2014 Jul 29;11:11. doi: 10.1186/1742-4933-11-11. eCollection 2014.

11.
12.

Nucleic acid reference materials (NARMs): definitions and issues.

Payne DA, Mamotte CD, Gancberg D, Pazzagli M, van Schaik RH, Schimmel H, Rousseau F; IFCC Committee for Molecular Diagnostics (C-MD).

Clin Chem Lab Med. 2010 Nov;48(11):1531-5. doi: 10.1515/CCLM.2010.313. Epub 2010 Oct 25. Review.

PMID:
20969510
13.

Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells.

Pocathikorn A, Taylor RR, Mamotte CD.

Clin Exp Pharmacol Physiol. 2010 Apr;37(4):471-6. doi: 10.1111/j.1440-1681.2009.05337.x. Epub 2009 Nov 23.

PMID:
19930424
14.

Phenylketonuria: an inborn error of phenylalanine metabolism.

Williams RA, Mamotte CD, Burnett JR.

Clin Biochem Rev. 2008 Feb;29(1):31-41.

15.

Directions for clinical practice improvement in HFE gene mutation testing.

Gillett MJ, Mamotte CD, Ravine D, Vasikaran SD.

Med J Aust. 2007 Sep 17;187(6):342-4.

PMID:
17874981
16.
17.

Genotyping of single nucleotide substitutions.

Mamotte CD.

Clin Biochem Rev. 2006 Feb;27(1):63-75.

18.

Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients.

Pace CS, Martin AM, Hammond EL, Mamotte CD, Nolan DA, Mallal SA.

Antivir Ther. 2003 Aug;8(4):323-31.

PMID:
14518702
19.

Endothelial nitric oxide synthase gene polymorphism, homocysteine, cholesterol and vascular endothelial function.

Bilsborough W, Green DJ, Mamotte CD, van Bockxmeer FM, O'Driscoll GJ, Taylor RR.

Atherosclerosis. 2003 Jul;169(1):131-8.

PMID:
12860259
20.

Evidence of reduced coronary artery disease risk for apolipoprotein epsilon2/3 heterozygotes.

Mamotte CD, Burke V, Taylor RR, van Bockxmeer FM.

Eur J Intern Med. 2002 Jun;13(4):250-255.

PMID:
12067821
21.

Hepatic lipase gene -514 C/T polymorphism and premature coronary heart disease.

Ji J, Herbison CE, Mamotte CD, Burke V, Taylor RR, van Bockxmeer FM.

J Cardiovasc Risk. 2002 Apr;9(2):105-13.

PMID:
12006918
22.

Angiotensin-converting enzyme gene polymorphism and premature coronary heart disease.

van Bockxmeer FM, Mamotte CD, Burke V, Taylor RR.

Clin Sci (Lond). 2000 Sep;99(3):247-51.

PMID:
11787479
23.
24.

A G5569A HFE gene polymorphism that interferes in DNA tests for genetic haemochromatosis: who needs to be re-tested?

Mamotte CD, Grzegurzko D, Lopes T, Sayer D, van Bockxmeer F, Christiansen F, Vasikaran S.

Clin Chem Lab Med. 2000 Aug;38(8):795-7. No abstract available.

PMID:
11071075
25.

Elite athletes and the gene for angiotensin-converting enzyme.

Taylor RR, Mamotte CD, Fallon K, van Bockxmeer FM.

J Appl Physiol (1985). 1999 Sep;87(3):1035-7.

26.

Butyrycholinesterase K variant and Alzheimer's disease.

Panegyres PK, Mamotte CD, Vasikaran SD, Wilton S, Fabian V, Kakulas BA.

J Neurol. 1999 May;246(5):369-70.

PMID:
10399868
27.

Comparison of the LDL-receptor binding of VLDL and LDL from apoE4 and apoE3 homozygotes.

Mamotte CD, Sturm M, Foo JI, van Bockxmeer FM, Taylor RR.

Am J Physiol. 1999 Mar;276(3):E553-7. doi: 10.1152/ajpendo.1999.276.3.E553.

PMID:
10070023
28.
29.

The effect of homocysteine on DNA synthesis in cultured human vascular smooth muscle.

Tang L, Mamotte CD, Van Bockxmeer FM, Taylor RR.

Atherosclerosis. 1998 Jan;136(1):169-73.

PMID:
9544744
30.

Methylenetetrahydrofolate reductase gene and coronary artery disease.

van Bockxmeer FM, Mamotte CD, Vasikaran SD, Taylor RR.

Circulation. 1997 Jan 7;95(1):21-3.

PMID:
8994411
31.

Familial defective apolipoprotein B-100 (FDB): effect of simvastatin therapy on LDL-receptor binding.

Mamotte CD, Sturm M, Foo JI, van Bockxmeer FM, Taylor RR.

Atherosclerosis. 1996 Aug 23;125(1):103-10.

PMID:
8831932
32.

Angiotensin-converting enzyme and apolipoprotein E genotypes and restenosis after coronary angioplasty.

van Bockxmeer FM, Mamotte CD, Gibbons FA, Burke V, Taylor RR.

Circulation. 1995 Oct 15;92(8):2066-71.

PMID:
7554183
33.

Apolipoprotein epsilon 4 homozygosity--a determinant of restenosis after coronary angioplasty.

van Bockxmeer FM, Mamotte CD, Gibbons FR, Taylor RR.

Atherosclerosis. 1994 Oct;110(2):195-202.

PMID:
7848369
34.

Urine albumin excretion in healthy subjects.

Dimmitt SB, Lindquist TL, Mamotte CD, Burke V, Beilin LJ.

J Hum Hypertens. 1993 Jun;7(3):239-43.

PMID:
8345490
35.
36.

Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease.

van Bockxmeer FM, Mamotte CD.

Lancet. 1992 Oct 10;340(8824):879-80.

PMID:
1357300

Supplemental Content

Loading ...
Support Center